Cambrex (CBM) Updates FY18 Earnings Guidance

Cambrex (NYSE:CBM) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share guidance of $2.80-3.03 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.85. The company issued revenue guidance of $524-545 million (Down 2% to Up 2%), compared to the consensus revenue estimate of $538.50 million.

Cambrex (NYSE CBM) opened at $51.80 on Friday. Cambrex has a 52-week low of $42.55 and a 52-week high of $62.95. The company has a market capitalization of $1,678.47, a PE ratio of 16.87, a PEG ratio of 1.20 and a beta of 2.38.

Cambrex (NYSE:CBM) last announced its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $1.27 EPS for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.17. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The business had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. During the same period in the previous year, the company posted $1.23 earnings per share. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. research analysts anticipate that Cambrex will post 2.85 EPS for the current fiscal year.

CBM has been the subject of a number of analyst reports. William Blair began coverage on Cambrex in a research report on Tuesday, January 16th. They set an outperform rating for the company. Craig Hallum reaffirmed a buy rating and issued a $60.00 price target (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. Finally, Zacks Investment Research raised Cambrex from a strong sell rating to a hold rating in a report on Monday, January 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $60.00.

ILLEGAL ACTIVITY NOTICE: “Cambrex (CBM) Updates FY18 Earnings Guidance” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit